IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
November 25, 2024 07:00 ET
|
IN8bio, Inc
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
October 04, 2024 08:30 ET
|
Biodexa Pharmaceuticals PLC
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...
aTyr Pharma Announces Research Study with Stanford Medicine
July 30, 2024 08:00 ET
|
aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
April 30, 2024 06:05 ET
|
IN8bio, Inc
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
Glioma Treatment Market worth $8.29 Billion by 2030 - Exclusive Report by The Insight Partners
September 22, 2023 08:54 ET
|
The Insight Partners
Pune, India, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Glioma is a condition that covers a broad category of brain and spinal cord tumors that concern the glial cells in the brain function and can be fatal...
RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
November 15, 2022 06:00 ET
|
RadioMedix Inc.
Houston, TX, USA and Marseille, France, Nov. 15, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Vect-Horus are pleased to announce that they have successfully dosed the first patients in an exploratory...
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
October 07, 2022 08:00 ET
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for...
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
July 26, 2022 07:30 ET
|
Diffusion Pharmaceuticals Inc.
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
October 19, 2021 18:12 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
August 17, 2021 09:25 ET
|
Lixte Biotechnology Holdings, Inc.
A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...